While HFA quickly changed the direction of its annual Symposium in 2020 to a virtual conference instead of an in-person event due to COVID-19 state restrictions, we knew it was still important to showcase the research taking place in the bleeding disorders community. Sharing research with the community helps patients to better understand why researchers gather data and what those findings mean to the community. It also helps to encourage patients and their families to participate in future research. In 2020, our online Symposium featured a virtual room where researchers could display their findings and chat with attendees. Below are the posters featured at the 2020 Virtual Symposium.
Recent Progress in the Development Program of AMT 061 (Etranacogene Dezaparvovec) for Persons with Severe or Moderately Severe Hemophilia B |
Early Patient Experiences with Emicizumab in the United States: A Qualitative Study |
Cell Therapy in Hemophilia: What the Future Holds |
Factor VIII Use in the Treatment of Breakthrough Bleeds in Persons with Hemophilia A Without Inhibitors on Emicizumab Prophylaxis: The Phase III HAVEN 3 Study Experience |
Managing Anaphylaxis to Factor VIII |
Gender Differences in Parenting Stress and Social Support Among Hemophilia Families |
Decreased Inhibitor Formation in Previously Untreated Patients with Severe Hemophilia A Exposed to a 4th Generation Rfviii Product Derived From a Human Cell Line – Simoctocog Alfa, Nuwiq |
An Evaluation of Health Utility And Quality of Life In Hemophilia: A Systematic Literature Review |
Clinical Validation of the Haemo-Qol-A After Valoctocogene Roxaparvovec Treatment: Results From 2 Studies |
Pharmacovigilance of Von Willebrand Factor/Coagulation Fviii Complex (Human) 10 Years’ Experience |
Congratulations to our top winners of our 2020 Symposium Poster Session
Read more about the winners in this Dateline article.
